130 related articles for article (PubMed ID: 9298937)
21. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts.
Gabrilovich DI; Ciernik IF; Carbone DP
Cell Immunol; 1996 May; 170(1):101-10. PubMed ID: 8665590
[TBL] [Abstract][Full Text] [Related]
22. Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity.
Cao X; Zhang W; He L; Xie Z; Ma S; Tao Q; Yu Y; Hamada H; Wang J
J Immunol; 1998 Dec; 161(11):6238-44. PubMed ID: 9834111
[TBL] [Abstract][Full Text] [Related]
23. Dendritic cell-tumor coculturing vaccine can induce antitumor immunity through both NK and CTL interaction.
Kim KD; Choi SC; Kim A; Choe YK; Choe IS; Lim JS
Int Immunopharmacol; 2001 Nov; 1(12):2117-29. PubMed ID: 11710541
[TBL] [Abstract][Full Text] [Related]
24. Specificity and efficacy of dendritic cell-based vaccination against tuberculosis with complex mycobacterial antigens in a mouse model.
Rubakova E; Petrovskaya S; Pichugin A; Khlebnikov V; McMurray D; Kondratieva E; Baturina I; Kondratieva T; Apt A
Tuberculosis (Edinb); 2007 Mar; 87(2):134-44. PubMed ID: 17011827
[TBL] [Abstract][Full Text] [Related]
25. Uric acid enhances T cell immune responses to hepatitis B surface antigen-pulsed-dendritic cells in mice.
Ma XJ; Tian DY; Xu D; Yang DF; Zhu HF; Liang ZH; Zhang ZG
World J Gastroenterol; 2007 Feb; 13(7):1060-6. PubMed ID: 17373740
[TBL] [Abstract][Full Text] [Related]
26. [Ad hTRP2 - mediated immunity against melanoma is enhanced by dendritic cells pulsed with peptide].
Tan XH; Liu C; Wan YH
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):658-61. PubMed ID: 17274369
[TBL] [Abstract][Full Text] [Related]
27. DC-based vaccine loaded with acid-eluted peptides in acute myeloid leukemia: the importance of choosing the best elution method.
Delluc S; Tourneur L; Fradelizi D; Rubio MT; Marchiol-Fournigault C; Chiocchia G; Buzyn A
Cancer Immunol Immunother; 2007 Jan; 56(1):1-12. PubMed ID: 16676183
[TBL] [Abstract][Full Text] [Related]
28. In vivo priming of natural killer T cells by dendritic cells pulsed with hepatoma-derived acid-eluted substances.
Ishii R; Shimizu M; Nakagawa Y; Shimizu K; Tanaka S; Takahashi H
Cancer Immunol Immunother; 2004 May; 53(5):383-90. PubMed ID: 14624311
[TBL] [Abstract][Full Text] [Related]
29. Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100.
Panelli MC; Wunderlich J; Jeffries J; Wang E; Mixon A; Rosenberg SA; Marincola FM
J Immunother; 2000; 23(4):487-98. PubMed ID: 10916759
[TBL] [Abstract][Full Text] [Related]
30. In vitro immunization of patient T cells with autologous bone marrow antigen presenting cells pulsed with tumor lysates.
Coulon V; Ravaud A; Gaston R; Delaunay M; Pariente JL; Verdier D; Scrivante V; Gualde N
Int J Cancer; 2000 Dec; 88(5):783-90. PubMed ID: 11072249
[TBL] [Abstract][Full Text] [Related]
31. IL-12 is both required and sufficient for initiating T cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-pulsed dendritic cells.
Bianchi R; Grohmann U; Belladonna ML; Silla S; Fallarino F; Ayroldi E; Fioretti MC; Puccetti P
J Immunol; 1996 Aug; 157(4):1589-97. PubMed ID: 8759743
[TBL] [Abstract][Full Text] [Related]
32. Enhanced therapeutic efficacy of tumor RNA-pulsed dendritic cells after genetic modification with lymphotactin.
Zhang W; He L; Yuan Z; Xie Z; Wang J; Hamada H; Cao X
Hum Gene Ther; 1999 May; 10(7):1151-61. PubMed ID: 10340547
[TBL] [Abstract][Full Text] [Related]
33. [Inhibitory effect of dendritic cells pulsed with MAGE-3 peptide on transplanted murine gastric cancer in mice].
Lü B; Liu BY; Zhang Y; Chen XH; Zhu ZG; Yin HR; Lin YZ
Zhonghua Yi Xue Za Zhi; 2005 Aug; 85(30):2120-3. PubMed ID: 16313822
[TBL] [Abstract][Full Text] [Related]
34. Antitumor vaccination effect of dendritic cells can be augmented by locally utilizing Th1-type cytokines from OK432-reactive CD4+ T cells.
Tamada K; Harada M; Abe K; Li T; Tada H; Onoe Y; Nomoto K
Cancer Immunol Immunother; 1998 May; 46(3):128-36. PubMed ID: 9625536
[TBL] [Abstract][Full Text] [Related]
35. Synergistic combination of murine bone marrow-derived dendritic cells loaded ex vivo with whole tumor lysate and systemic chemotherapy mediates antitumor immune responses in vivo.
Salem ML; Nassef M; Gomaa S; Essa I
Biomed Pharmacother; 2017 Sep; 93():286-295. PubMed ID: 28648976
[TBL] [Abstract][Full Text] [Related]
36. Dendritic cells transduced with protein antigens induce cytotoxic lymphocytes and elicit antitumor immunity.
Shibagaki N; Udey MC
J Immunol; 2002 Mar; 168(5):2393-401. PubMed ID: 11859130
[TBL] [Abstract][Full Text] [Related]
37. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
Wang J; Saffold S; Cao X; Krauss J; Chen W
J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
[TBL] [Abstract][Full Text] [Related]
38. Direct and indirect T cell priming by dendritic cell vaccines.
Cayeux S; Richter G; Becker C; Pezzutto A; Dörken B; Blankenstein T
Eur J Immunol; 1999 Jan; 29(1):225-34. PubMed ID: 9933104
[TBL] [Abstract][Full Text] [Related]
39. Bone marrow-derived dendritic cells pulsed with tumor lysates induce anti-tumor immunity against gastric cancer ex vivo.
Li YL; Wu YG; Wang YQ; Li Z; Wang RC; Wang L; Zhang YY
World J Gastroenterol; 2008 Dec; 14(46):7127-32. PubMed ID: 19084922
[TBL] [Abstract][Full Text] [Related]
40. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.
Maitre N; Brown JM; Demcheva M; Kelley JR; Lockett MA; Vournakis J; Cole DJ
Clin Cancer Res; 1999 May; 5(5):1173-82. PubMed ID: 10353754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
